MOTS-c

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) with the sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg and an approximate molecular weight of 2175 Da. It was discovered in 2015 by Dr. Changhan Lee and Dr. Pinchas Cohen at the Leonard Davis School of Gerontology, University of Southern California. MOTS-c is encoded within the 12S rRNA gene of mitochondrial DNA (mtDNA), making it one of only a handful of known functional peptides encoded by the mitochondrial genome, alongside humanin (the first identified MDP, discovered in 2001) and SHLP1-6.

The mechanism of action represents a paradigm shift in understanding mitochondrial function. Traditionally, mitochondria were viewed as passive energy generators regulated entirely by the nucleus. MOTS-c demonstrates that mitochondria send active signals back to the nucleus (retrograde signaling) to regulate metabolic gene expression. Under metabolic stress, MOTS-c translocates from the cytoplasm into the nucleus, where it interacts with the antioxidant response element (ARE) in gene promoters, activating the Nrf2 (nuclear factor erythroid 2-related factor 2) transcriptional pathway. This regulates expression of antioxidant genes (NQO1, GCLC, HMOX1) and genes involved in one-carbon/folate metabolism (SHMT2, MTHFD2).

MOTS-c activates AMPK (AMP-activated protein kinase) in skeletal muscle through a mechanism that involves inhibition of the folate cycle and de novo purine biosynthesis, leading to accumulation of the intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which is an endogenous AMPK activator. This creates a metabolic cascade: MOTS-c -> folate cycle inhibition -> AICAR accumulation -> AMPK activation -> increased glucose uptake (GLUT4 translocation), enhanced fatty acid oxidation (ACC phosphorylation), and mitochondrial biogenesis (PGC-1alpha activation).

In the discovery publication in Cell Metabolism (2015, DOI: 10.1016/j.cmet.2015.02.009), Lee et al. demonstrated that MOTS-c prevented diet-induced obesity in mice fed a high-fat diet (60% calories from fat). Treated mice showed significantly reduced weight gain, improved glucose tolerance (OGTT), and reduced hepatic steatosis (fatty liver) despite continuing the obesogenic diet. In aged mice (22 months), MOTS-c improved physical performance on treadmill testing and reversed age-dependent insulin resistance, restoring glucose homeostasis to levels comparable to young animals.

Circulating MOTS-c levels decline with age in humans and are inversely correlated with markers of metabolic syndrome and type 2 diabetes. Exercise acutely increases circulating MOTS-c levels in skeletal muscle and plasma, suggesting that MOTS-c may be one of the molecular mediators through which exercise produces its metabolic benefits. This positions MOTS-c as an endogenous exercise mimetic, a signal normally produced during physical activity that can be supplemented externally when exercise capacity is limited by age, disability, or illness.

Pharmacokinetically, MOTS-c is administered by subcutaneous injection. Plasma half-life after SC injection is estimated at 2-4 hours. The peptide distributes to skeletal muscle, liver, and adipose tissue, its primary target organs. Nuclear translocation under metabolic stress conditions extends its functional activity beyond its plasma half-life by initiating transcriptional programs that persist for hours to days. Dosing protocols in mouse studies used daily or every-other-day injections for 2-4 weeks.

For storage, MOTS-c should be stored as lyophilized powder at -20C for long-term stability or 2-8C for up to 30 days. Reconstitute with bacteriostatic water or sterile 0.9% saline. Reconstituted solutions should be kept at 2-8C and used within 14-21 days. The peptide contains two methionine residues (positions 1 and 6) susceptible to oxidation; minimize air exposure and protect from light. Stable at pH 5-7 in aqueous solution.

Safety observations from preclinical studies in mice showed no adverse effects from daily MOTS-c injections over 4-week treatment periods. No hepatotoxicity, nephrotoxicity, or hematological changes were observed. Body weight decreased in obese animals but did not decline below healthy levels in lean animals, suggesting a homeostatic rather than pathological mechanism. MOTS-c is an endogenous human peptide naturally present in circulation, and exogenous administration restores declining age-related levels. Formal human clinical trials are in progress but have not yet reported results.